Background {#Sec1}
==========

Prophylactic cranial irradiation (PCI) is a standard treatment for patients with limited-stage small cell lung cancer (SCLC) who have a good response to initial therapy \[[@CR1]\]. Similarly, in patients with extensive-stage SCLC that has responded to systemic therapy, PCI decreases brain metastases (BMs) \[[@CR2]\]. Recently, the cognitive deficits after cranial radiation attracted researchers' attention. Brown \[[@CR3]\] et al. reported that among patients with 1 to 3 brain metastases, the use of stereotactic radiosurgery (SRS) alone, compared with SRS combined with whole brain radiation therapy (WBRT), resulted in less cognitive deterioration at 3 months. Similar decline in Hopkins Verbal Learning Test-Revised (HVLT-R) and quality of life (QOL) has also been observed after PCI for lung cancer \[[@CR4]\]. Although neurocognitive disorders after WBRT/PCI have a multifactorial etiology, it is currently believed that they are mostly caused by a loss of neural stem cells (NSCs) \[[@CR5]\]. Transplantation experiments demonstrate that NSCs are restricted in the postnatal brain to regions in which they occur naturally, namely the subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampus \[[@CR6], [@CR7]\]. Several exogenous and endogenous conditions negatively regulate neurogenesis in these regions, including chemotherapy, radiation therapy, glucocorticoid stress hormones and certain inflammatory states. In conclusion, avoidance of hippocampus in WBRT/PCI appears to be of essence.

Up to now, only one study with a small sample size has been carried out to estimate the risk of metastases in the hippocampal avoidance (HA) region for patients with SCLC \[[@CR8]\]. Although existing radiotherapy technique has already certified the feasibility of sparing the hippocampus, whether HA increases the risk of inadequate dosage for BMs is unknown. The purpose of this retrospective research is to assess the feasibility of selectively sparing the hippocampus during PCI for SCLC patients and to analyze the impact of the distribution and dosimetry of BMs regarding to the NSC regions (especially hippocampus).

Methods {#Sec2}
=======

Inclusion criteria {#Sec3}
------------------

Consecutive SCLC patients with BMs who were treated in the Radiation Oncology Clinic of Shanghai Chest Hospital from Jan 2011 to Oct 2014 were reviewed respectively. All cases were pathologically confirmed. T1-weighted, postcontrast, axial enhanced MR images dated right at the time of diagnosing BMs were required for each patient. 71.8% of the patients enrolled received WBRT sometime after diagnosis of BMs, while others did not as they refused the treatment or because of other clinical factors.

Exclusion criteria {#Sec4}
------------------

Patients who had received pre-treatment (radiotherapy or surgery) for brain from other diseases were excluded. Those who had been treated with PCI or pathologically diagnosed as combined SCLC were not included as well. There was no cut-off for the total number of metastases found in a single patient.

Study design {#Sec5}
------------

T1-weighted, postcontrast, axial enhanced MR images dated right at the time of diagnosing BMs were retrieved by both a radiologist and a radiation oncologist for each patient. Axial images were used to outline the hippocampi, SVZ as well as the metastases. The anatomic boundaries of the hippocampus were identified according to the RTOG0933 hippocampal atlas \[[@CR9]\]. Metastases in the HA region were defined as lesions within the bilateral hippocampi plus \<5 mm of the surrounding area. The SVZs were defined as the 5 mm of tissue immediately adjacent to the lateral aspect of the lateral ventricle (Fig.[1a](#Fig1){ref-type="fig"} and [b](#Fig1){ref-type="fig"}).Fig. 1**a** Hippocampal metastasis. The *black* contour represents the hippocampal contour; the *arrow* points to the metastasis. **b** SVZ metastasis. The *black* contour represents the SVZ contour; the *arrow* points to the metastasis

The gross tumor volume (GTV) was volumetrically contoured on fused diagnostic enhanced T1 weighted MRI-planning CT images. GTV for each target metastasis was identified as the enhanced lesion within 5-15 mm from the hippocampus (peri-hippocampus) on the T1-weighted MRI. Planning target volume (PTV) was outlined using a computer-automated 3 mm 3D margin expansion of the GTV. The treatment planning system was Pinnacle^3^ treatment-planning workstation (Philips Healthcare, Andover, MA, USA; ADCA, Milpitas, CA, USA).

Method of HA {#Sec6}
------------

To detect whether the risk of BMs in peri-hippocampus area is increased by low dose exposure caused by HA, the implementation of IMRT plans are imitated for the patients. For hippocampal contouring and HA-PCI planning, bilateral hippocampi contours were manually generated on the fused MRI-CT image set and expanded by 5 mm to generate the HA regions. The PCI clinical target volume (PCI-CTV) was defined as the whole-brain parenchyma, and the PCI-PTV was defined as the PCI-CTV excluding the HA region. IMRT was delivered to a dose of 25Gy in 10 fractions over 2 weeks to cover the PCI-PTV while avoiding the hippocampus. In HA-PCI planning protocol, a dose up to 100% of the hippocampus could not exceed 9Gy, and the maximal hippocampal dose could not exceed 16Gy. In addition, the acceptable variation for the PCI-PTV was D~95%~ ≥ 25Gy, while D~1%~ \< 23.75Gy that identified as the "cold" spots was unacceptable (Fig.[2](#Fig2){ref-type="fig"}).Fig. 2The Dose Volume Histogram of HA-PCI

Statistical methods {#Sec7}
-------------------

Total metastases from all enrolled patients were assessed. All reported lesions were localized to the NSC compartments or the rest of the brain. Individual patients were categorized by the total number of intracranial metastases (oligometastatic:1--3 metastases; non-oligometastatic:4 or more metastases), the therapy processes (BM identified at diagnosis; BM identified during or after treatments) and the symptoms (symptomatic BM; asymptomatic BM). Then, the corresponding incidence of metastases in NSC regions was analyzed. Chi-square test was adopted to compare the incidence between different groups. A two-side *P* value \<0.05 was used for statistical significance.

Patients who have metastases within 15 mm from the hippocampus were evaluated separately. Of these cases, the number of patients and target metastases that can not reach the acceptable variation for the PCI-PTV were recorded, including those who already have HA region involved. Then, the ratio of patients and metastases with inadequate dosage were recorded.

Results {#Sec8}
=======

From Jan 2011 to Oct 2014, 238 SCLC patients with BMs were enrolled for the research. Demographic and disease-specific data of all patients are presented in Table [1](#Tab1){ref-type="table"}. The majority of the patients were male (89.5%), smoker or former smokers (84.5%). And approximately three quarters of patients were in Recursive Partitioning Analysis (RPA) class II (74.8%).Table 1Patient characteristics (*n* = 238)Number (%)Age  \> 60y126 (52.9%)  ≤ 60y112 (47.1%)Gender Male213 (89.5%) Female25 (10.5%)Smoking status Smoker or former smoker201 (84.5%) Nonsmoker37 (15.5%)RPA I46 (19.3%) II178 (74.8%) III14 (5.9%)Total number of intracranial metastases Oligometastatic150 (63.0%) Non-oligometastatic88 (37.0%)Therapy processes BMs identified at diagnosis97 (40.8%) BMs identified during or after treatments141 (59.2%)Symptoms Symptomatic BMs65 (27.3%) Asymptomatic BMs173 (72.7%)*RPA* recursive partitioning analysis, *BMs* brain metastases

The overall ratio of metastatic lesions located in NSC regions was 2.0% in the 1511 total metastases (30/1511). Among the NSC region metastases, 15 (1.0%) lesions involved the HA region of 14 (5.9%) patients and another 15 (1.0%) involved the SVZ of 15 (6.3%) patients, as Table [2](#Tab2){ref-type="table"} shows. 6 (2.5%) patients have the HA region and the SVZ affected simultaneously, while only 1 (0.4%) patient has bilateral hippocampi involved. Among the 14 patients with metastases in the HA region, a total of 480 lesions and 34.3 metastases per patient were observed. Meanwhile, among the 15 patients with SVZ metastases, there were a total of 480 metastatic lesions and 32 metastases per patient. So, even among the patients with a heavy burden of metastases, HA region and SVZ involvements both accounted for only 3.1% (15/480) of their total lesions.Table 2Pattern of involvements in patients with NSC region metastases and incidence of NSC lesions in different groupsSVZPHippocampus^a^PNo. of involved patients (%)15^a^ (6.3%)\_14^a^ (5.9%)\_No. of specific metastases in involved patients (%)15 (1.0%)\_15^b^ (1.0%)\_Total Number of intracranial metastases Oligometastatis pts0/150 (0.0%)0.0001/150 (0.7%)0.000 Non-oligometastatic pts15/88 (17.0%)13/88 (14.8%)Therapy processes BMs identified at Diagnosis3/97 (3.1%)0.1096/97 (6.2%)1.000 BMs identified during or after treatments12/141 (8.5%)8/141 (5.7%)Symptoms Symptomatic BMs5/65 (7.7%)0.5611/65 (1.5%)0.120 Asymptomatic BMs10/173 (5.8%)13/173 (7.5%)*SVZ* subventricular zone, *pts* patients, *BMs* brain metastases^a^Including 6 patients have hippocampus and SVZ simultaneously implicated^b^1 patient has bilateral hippocampi involved

The incidence of NSC region involved is listed in Table [2](#Tab2){ref-type="table"}, categorized based on different clinical conditions, i.e. the total number of intracranial metastases, the therapy processes and the symptoms. Throughout the patients, the difference of the incidence of HA region or SVZ involved was significant between oligmetastatic and non-oligmetastatic patients (*P* \< 0.05), but trivial for patients with different therapy processes and symptoms.

Of all patients enrolled, 36 patients had 48 additional lesions located within 15 mm from the hippocampus, except the 15 HA region involvements. Among theses 48 lesions, 26 target metastases in 18 patients can not reach the acceptable variation, i.e. PCI-PTV of D~95%~ ≥ 25Gy. As described in Table [3](#Tab3){ref-type="table"}, totally 26 (10.9%) patients with 41 (2.7%) metastases within 15 mm from the hippocampus had inadequate dosage in our group when HA-PCI was delivered.Table 3The evaluation of underdosage in brain treated with PCI according to the different criteria of HADifferent criteria of HAUnderdosageNo. of patients (%)No. of lesions (%)Spatial distribution≤5 mm from hippocampus14 (5.9%)15 (1.0%)≤15 mm from hippocampus40 (16.8%)63 (4.2%)Dose distributionHippocampus: D~100~ ≤ 9Gy\
D~max~ ≤ 16Gy26 (10.9%)41 (2.7%)*HA* hippocampal avoidance

Discussion {#Sec9}
==========

Whether HA-PCI in SCLC is worthwhile or not remains unclear so far. Most studies focus on its security and feasibility. And research targeting at the reduction of normal cerebral tissue injury is still in progress. To date, several studies have investigated the incidence of metastases in HA region (Table [4](#Tab4){ref-type="table"}) to identify the security of HA-WBRT \[[@CR8]--[@CR13]\]. However, it is worth noting that since most researchers didn't impose restrictions on primary site of BMs, SCLC patients only accounted for a small fraction.Table 4Distribution of brain metastases in HA region for SCLC patientsStudyKundapur et al. \[[@CR8]\]Gondi et al. \[[@CR9]\]Ghia et al. \[[@CR10]\]Marsh et al. \[[@CR11]\]Wan et al. \[[@CR12]\]Harth et al. \[[@CR13]\]No of metastatic lesionsNA11312726972270856No of ptsNA371100107488100No of metastases in HA region (%)NA34 (3.0%)9 (3.3%)16 (2.3%)7 (0.3%)11 (1.3%)No of pts. with metastases in HA region (%)NA22 (8.6%)8 (8.0%)16 (15.0%)7 (1.4%)11 (11.0%)No of metastatic lesions for SCLC pts359NA24145225201No of SCLC pts593810114411No of metastases in HA region for SCLC pts. (%)3 (0.8%)NA3 (12.5%)3 (2.1%)1 (0.4%)5 (2.5%)No of SCLC pts. with metastases in HA region (%)3 (5.1%)4 (10.5%)3 (30.0%)3 (27.3%)1 (2.3%)5 (45.5%)*pts* patients, *HA* hippocampal avoidance, *SCLC* small cell lung cancer, *NA* not available

Even though PCI offers clinically proven safety and satisfactory therapeutic efficacy to SCLC patients, it induces adverse effects like neurocognitive deficits \[[@CR14]\]. Consequently, HA-PCI needs to be treated with caution. In previous work, some researchers noted that the metastatic incidence of the HA region in patients with SCLC seemed to be higher than that of the others \[[@CR11], [@CR13]\]. Nevertheless, Gondi and colleagues \[[@CR9]\] reported only 4 HA region metastases in 38 patients with SCLC (10.5%) and Wan et al. \[[@CR12]\] even reported smaller rate with only 1 in 44 SCLC patients (3.0%). Such data may be skewed because of the limited sample size. Recently, Kundapur et al. \[[@CR8]\] first assessed the risk of metastases in the HA region for SCLC patients. Of 59 patients with BMs, 3 (5.0%) had metastases in the HA region, and collectively there were 359 BMs with 3(0.8%) deposits. However, relevant data for such group were still limited. The work here founds out that the rate of involvement of the HA region to be 5.9% overall, very close to the recent research. And the incidence was not so high as described in others' work. Up to now, this is the largest sample size study for SCLC patients, in which both patients diagnosed as combined SCLC and patients received PCI previously were excluded.

Only one study from Fudan University Shanghai Cancer Center has reviewed the metastatic involvement of the SVZ until now. Wan et al. \[[@CR12]\] indicated that the rate of involvement of the SVZ was 0.8% (18/2270) for all intracranial metastases and 3.7% (18/488) for all patients. In our retrospective review, this rate was 1.0% (15/1511) for all intracranial metastases and 6.3% (15/238) for all patients. These results showed the incidence of BMs within the SVZ was also very low. Moreover, our work concludes that the involvement incidence of the NSC regions was lower with the oligometastatic patients than with the non-oligometastatic patients (*P* \< 0.05). Similar results were also reported by Marsh \[[@CR11]\] and Wan \[[@CR12]\] et al. Given that the high rate of NSC regions metastases occurred to SCLC patients with non-oligometastatic disease, more attention must be paid to this subgroup. Whether HA-PCI should be performed in different strategies with certain patients need to be considered with caution.

It poses important challenges to avoid the hippocampus during cranial irradiation while allowing for uniform dose delivery to the remainder of the brain, because of the central location and the unique anatomic shape of the hippocampus. Recently, many planning studies have shown the dosimetric feasibility of HA-WBRT using different radiotherapy systems \[[@CR15]\]. Similarly, as for BMs treatment, HA-WBRT technique can be used for PCI where the neurocognitive function (NCF) preserving approaches are even more justified. Investigators at Rush University Medical Center \[[@CR16]\] tested the feasibility of dosimetrically sparing the hippocampus and the SVZ during helical TomoTherapy with WBRT and PCI. They finally revealed the fact that PCI differs from WBRT only in terms of fractionation and that the standard radiotherapy technique is similar. Thus, it is now technically and dosimetrically feasible to implement HA approaches into clinical practice.

At present, HA region is defined as the bilateral hippocampi plus \<5 mm of the surrounding area generated on the fused MRI-CT image set in most studies including RTOG0933. A lesser dose would be applied to this defined region (HA) as compared with the remaining part of the brain. Additionally, some investigators \[[@CR10]\] considered the area with the distance of 5 to 15 mm from the hippocampus to be the high-risk region. Metastases located in this high-risk region may have inadequate dosage in HA-PCI. To validate this problem, HA-PCI planning was implemented in patients with metastases within 15 mm from the hippocampus in our study. Ultimately, 36 patients had 48 lesions located in this high-risk area, and 26 target metastases in 18 patients can not reach the acceptable variation for the PCI-PTV. Together with the HA region involvements, 26 (10.9%) patients with 41 (2.7%) metastases had adequate dosage in HA-PCI. Yet, though it only affected 2.7% of the lesions, the proportion was over 10% for the patients. Therefore, conclusion may be drawn that about 10% of patients may have adequate dosage due to HA-PCI treatment. But we believe that this is still an acceptable clinical treatment strategy for SCLC. As relevant data have not been evaluated before, the problem needs further attention.

Another puzzling issue is that the majority of the patients enrolled were men (89.5%). SCLC had historically been seen more frequently in men than in women. However, in the latest study, Wang et al. \[[@CR17]\] found the patient number in both sexes became similar over the last two decades due to decreasing male cases and a stable number of female cases in the United States. Similarly, Schabath et al. \[[@CR18]\] assessed demographic characteristics of 1032 SCLC patients treated at the Moffitt Cancer Center from 1986 to 2008. The result showed 50.2% of the cases were male, which was quite different from ours. The main reason for our result is tobacco smoking \[[@CR19]\], which is strongly associated with the development of SCLC, with only 2 to 3% of patients being never-smokers \[[@CR20]\]. In China, the main smokers are men, who constitute the major portion of the SCLC. The percentage of women smokers is extremely low, and none of the female patients in our study has a history of smoking. So, the differences of smoking status between different races and nationalities may explain the problem.

Our data are limited by the fact that this is a retrospective, single-institution study. The statuses of BMs were not original and were affected by many factors, including the following frequency, the appearance of symptoms, etc. As shown in this research, which has the largest sample among peers' work, the risk of BMs in NSC regions is extremely low and about 10% of patients may have adequate dosage due to HA-PCI treatment. Therefore, it is reasonable to selectively reduce dose to the hippocampus, while simultaneously to treat the remainder of the whole brain with full dose as far as possible during PCI for SCLC patients. Some problems, such as the recurrence rate of high-risk region and the preservation of cognitive function after HA-PCI, need to be further explored in the future.

Conclusions {#Sec10}
===========

Our retrospective review of 1511 metastases in 238 patients (among whom 89.5% were male) suggests that the rate of involvement of the NSC regions (especially hippocampus) by intracranial metastatic disease in SCLC is very low and is limited primarily to non-oligometastatic disease with a heavy tumor burden. Also, dosimetric analysis shows that about 10% of patients may have adequate dosage due to HA-PCI treatment. But we believe that this is still an acceptable clinical treatment strategy for SCLC. These results provide a theoretical principle in support of investigating the potential benefits of HA-PCI for SCLC.
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